Aktive Positionen von Pieter Oldenziel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ABLYNX | Direktor/Vorstandsmitglied | 01.01.2019 | - |
Sanofi Foreign Participations BV
 Sanofi Foreign Participations BV Pharmaceuticals: GenericHealth Technology Part of Sanofi, Sanofi Foreign Participations BV is a Dutch company that manufactures human monoclonal antibody drugs. The company is based in Amsterdam, Netherlands. The company was founded in 1998. The CEO is Pieter Oldenziel. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Pieter Oldenziel
Statistik
International
| Belgien | 2 |
| Niederlande | 2 |
Operativ
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Sanofi Foreign Participations BV
Sanofi Foreign Participations BV Pharmaceuticals: GenericHealth Technology Part of Sanofi, Sanofi Foreign Participations BV is a Dutch company that manufactures human monoclonal antibody drugs. The company is based in Amsterdam, Netherlands. The company was founded in 1998. The CEO is Pieter Oldenziel. | Health Technology |
- Börse
- Insiders
- Pieter Oldenziel
- Erfahrung
